Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma

The case for aggressive management

Koen W. Van Besien, Issa F. Khouri, Sergio A. Giralt, Philip McCarthy, Rakesh Mehra, Borje S. Andersson, Donna Przepiorka, James L. Gajewski, Nagendranath Bellare, Rajneesh Nath, Jorge E. Romaguera, Peter McLaughlin, Martin Korbling, Albert B. Deisseroth, Fernando F. Cabanillas, Richard E. Champlin

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% ± 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.

Original languageEnglish (US)
Pages (from-to)1096-1102
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number5
StatePublished - May 1995
Externally publishedYes

Fingerprint

Homologous Transplantation
Case Management
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Autologous Transplantation
Survival Rate
Prospective Studies
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Besien, K. W., Khouri, I. F., Giralt, S. A., McCarthy, P., Mehra, R., Andersson, B. S., ... Champlin, R. E. (1995). Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. Journal of Clinical Oncology, 13(5), 1096-1102.

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma : The case for aggressive management. / Van Besien, Koen W.; Khouri, Issa F.; Giralt, Sergio A.; McCarthy, Philip; Mehra, Rakesh; Andersson, Borje S.; Przepiorka, Donna; Gajewski, James L.; Bellare, Nagendranath; Nath, Rajneesh; Romaguera, Jorge E.; McLaughlin, Peter; Korbling, Martin; Deisseroth, Albert B.; Cabanillas, Fernando F.; Champlin, Richard E.

In: Journal of Clinical Oncology, Vol. 13, No. 5, 05.1995, p. 1096-1102.

Research output: Contribution to journalArticle

Van Besien, KW, Khouri, IF, Giralt, SA, McCarthy, P, Mehra, R, Andersson, BS, Przepiorka, D, Gajewski, JL, Bellare, N, Nath, R, Romaguera, JE, McLaughlin, P, Korbling, M, Deisseroth, AB, Cabanillas, FF & Champlin, RE 1995, 'Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management', Journal of Clinical Oncology, vol. 13, no. 5, pp. 1096-1102.
Van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. Journal of Clinical Oncology. 1995 May;13(5):1096-1102.
Van Besien, Koen W. ; Khouri, Issa F. ; Giralt, Sergio A. ; McCarthy, Philip ; Mehra, Rakesh ; Andersson, Borje S. ; Przepiorka, Donna ; Gajewski, James L. ; Bellare, Nagendranath ; Nath, Rajneesh ; Romaguera, Jorge E. ; McLaughlin, Peter ; Korbling, Martin ; Deisseroth, Albert B. ; Cabanillas, Fernando F. ; Champlin, Richard E. / Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma : The case for aggressive management. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 5. pp. 1096-1102.
@article{eaab4f904b17449991b1bd2587324c0c,
title = "Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management",
abstract = "Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80{\%} ± 12.6{\%}. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.",
author = "{Van Besien}, {Koen W.} and Khouri, {Issa F.} and Giralt, {Sergio A.} and Philip McCarthy and Rakesh Mehra and Andersson, {Borje S.} and Donna Przepiorka and Gajewski, {James L.} and Nagendranath Bellare and Rajneesh Nath and Romaguera, {Jorge E.} and Peter McLaughlin and Martin Korbling and Deisseroth, {Albert B.} and Cabanillas, {Fernando F.} and Champlin, {Richard E.}",
year = "1995",
month = "5",
language = "English (US)",
volume = "13",
pages = "1096--1102",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma

T2 - The case for aggressive management

AU - Van Besien, Koen W.

AU - Khouri, Issa F.

AU - Giralt, Sergio A.

AU - McCarthy, Philip

AU - Mehra, Rakesh

AU - Andersson, Borje S.

AU - Przepiorka, Donna

AU - Gajewski, James L.

AU - Bellare, Nagendranath

AU - Nath, Rajneesh

AU - Romaguera, Jorge E.

AU - McLaughlin, Peter

AU - Korbling, Martin

AU - Deisseroth, Albert B.

AU - Cabanillas, Fernando F.

AU - Champlin, Richard E.

PY - 1995/5

Y1 - 1995/5

N2 - Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% ± 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.

AB - Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% ± 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.

UR - http://www.scopus.com/inward/record.url?scp=0029004847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029004847&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1096

EP - 1102

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -